Fangzhou and Innovent Biologics Partner to Integrate AI and Innovative Therapies for Diabetes and Obesity Care in China

Fangzhou Inc. and Innovent Biologics Form Strategic Partnership to Enhance Metabolic Disease Care

On September 10, 2025, Fangzhou Inc. (06086.HK), a leader in AI-driven Internet healthcare, announced a strategic partnership with Innovent Biologics. The collaboration focuses on integrating digital health services with innovative therapies targeting metabolic diseases and weight management. Fangzhou’s founder and CEO, Dr. Xie Fangmin, and Innovent’s Vice President of Retail, Tan Zaiqiang, attended the signing ceremony in Shanghai.

Partnership Highlights

This alliance combines Fangzhou’s AI-powered “H2H” digital healthcare ecosystem with Innovent’s pipeline of novel diabetes and obesity treatments. The partnership introduces a model that merges AI technology, innovative medication, and personalized healthcare services.

China’s weight management market is accelerating, with JPMorgan projecting it could reach US$14.9 billion by 2030. Recognizing this, the Chinese government has prioritized healthy weight initiatives through campaigns like the 2024 “Weight Management Year” and the 2025 “Healthy China” framework.

Leadership Perspective

Dr. Xie Fangmin emphasized the partnership’s goal to combine breakthrough medicines with digital health tools to improve patient outcomes, initially focusing on diabetes and obesity.

Innovations in AI and Therapy

Fangzhou will implement its “XS Core” AI large language model, supporting five key applications:

• AI Medication Finder
• AI Health Manager
• AI Doctor Assistant
• AI Academic Assistant
• AI-Powered Search

These tools provide personalized, around-the-clock digital care and patient education.

Innovent’s Mazdutide, a next-generation weight management drug, has shown significant benefits in weight reduction and improvements in blood pressure, lipid profiles, and uric acid levels. It was recognized as one of the “Top 10 Most Anticipated Medicines” globally in 2025.

Through this partnership, patients will have easier access to medication guidance and ongoing monitoring via AI tools to improve treatment adherence. The companies plan to further expand AI-powered health management solutions, aiming to improve the quality and efficiency of chronic disease care in China.

About Innovent Biologics

Founded in 2011, Innovent Biologics develops and markets therapies across oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology.

About Fangzhou Inc.

Fangzhou Inc. (06086.HK) is China’s leading online chronic disease management platform, serving over 52 million registered users and nearly 230,000 physicians as of mid-2025. The company specializes in delivering personalized medical care and precision medicine solutions.

For more details, visit https://investors.jianke.com.

Media Contact

Xingwei Zhao
Associate Director of Public Relations
Email: pr@jianke.com

Disclaimer: This announcement contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially due to various factors. Readers should not place undue reliance on these statements.